Linda Barton
Nurse Practitioner · Asheville, NCNPI 1336254549
Payments from drug & device makers
Across 212 payments — averaging $36.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Lilly USA, LLC$848
- Insulet Corporation$406
- Amgen$246
- Novo Nordisk$198
- Abbott$172
- plus $1K from 23 others
What the payments were for
- Travel & lodging$2,92938%
- Food & beverage$4,76362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 55 | $4,449 |
| Lilly USA, LLC | 44 | $848 |
| Insulet Corporation | 14 | $406 |
| Amgen(2 entities) | 13 | $246 |
| Novo Nordisk | 11 | $198 |
| Abbott | 8 | $172 |
| Tandem Diabetes Care, Inc. | 5 | $130 |
| Boehringer Ingelheim | 9 | $118 |
| Sanofi-aventis U.S. LLC | 6 | $115 |
| Bayer | 3 | $109 |
| Cequr Corporation | 3 | $102 |
| BETA Bionics, Inc. | 4 | $91 |
| Ascendis Pharma Endocrinology Inc | 4 | $86 |
| Radius Health, Inc. | 3 | $85 |
| Corcept Therapeutics | 5 | $80 |
| Antares Pharma, Inc. | 4 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Dexcom, Inc. | 3 | $64 |
| AstraZeneca(2 entities) | 3 | $39 |
| Nevro Corp. | 2 | $37 |
| IBSA Pharma Inc. | 2 | $32 |
| Sequel Med Tech, LLC | 1 | $24 |
| Averitas Pharma Inc. | 1 | $23 |
| Amphastar Pharmaceuticals, Inc. | 1 | $21 |
| Gilead | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,798
- InPen$1,035
- Omnipod$118
How this compares
$7,692 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 635 | $921,524 |
| MounjaroTirzepatide | 529 | $749,147 |
| JardianceEmpagliflozin | 521 | $572,663 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 266 | $300,815 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 132 | $137,307 |
| TrulicityDulaglutide | 85 | $105,842 |
| FarxigaDapagliflozin Propanediol | 102 | $103,471 |
| Tresiba Flextouch U-200Insulin Degludec | 63 | $102,897 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $101,840 |
| Tresiba Flextouch U-100Insulin Degludec | 95 | $87,192 |
| KerendiaFinerenone | 89 | $70,374 |
| Novolog FlexpenInsulin Aspart | 162 | $66,601 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $66,346 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $57,056 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 46 | $54,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $198 | $995,002710 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $848 | $885,114702 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $118 | $739,872691 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $115 | $306,054292 claims |
| AstraZenecaFarxiga | $39 | $103,471102 claims |
| BayerKerendia | $109 | $70,37489 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Asheville
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
- Deborah AllenDurham$112K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
- Olivia OgburnWinston Salem$70K
- Bridget ArchambaultDurham$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.